"RNAi Therapeutics Market (2nd Edition), 2019-2030 - Roots Analysis
Roots Analysis has announced the addition of "RNAi Therapeutics Market (2nd Edition), 2019-2030" report to its list of offerings.
By: Roots Analysis
To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link
Key Market Insights
Over 170 RNAi therapeutics are currently under development
Nearly 30% of pipeline drugs are in the clinical phase, while the rest are either in the preclinical / discovery stage. The majority of pipeline drug candidates are delivered using siRNA conjugated delivery technology platform to mitigate targeted delivery to organ / cell.
More than 70% of ongoing clinical trials are being conducted in North America and Europe
In total, we came across over 100 clinical trials that have been / are being conducted across the globe. It is worth noting that around 40% of these trials were observed to be phase II studies. Further, 75% of the active clinical trials being conducted in this domain are evaluating siRNAs.
Over 36,000 patents were filed / granted related to RNAi therapeutics since 2014
Majority of these were patent applications (59%), followed by granted patents (40%). It is worth highlighting that both industry and non-industry players are actively involved in this domain. However, majority of the patents related to RNAi therapeutics were filed / granted by industry players (60%).
USD 5.4+ billion invested by both private and public investors, since 2014
Around USD 3 billion was raised through secondary offerings, representing more than 50% of the total capital raised by industry players till July 2019. Further, there have been five instances of debt financing, accounting for more than USD 844 million in financing of RNAi therapeutics related initiatives.
The research covers brief profiles, featuring an overview of the therapy, current development status and clinical results. Each profile includes information on therapeutic area, indication, targeted gene, route of administration, special designations, mechanism of action, dosage, patent portfolio, technology portfolio, clinical trials and recent developments (if available).
You may also be interested in the following titles:
• Gene Therapy Market (3rd Edition), 2019-2030 (https://www.rootsanalysis.com/
• Global T-Cell (CAR-T, TCR and TIL) Therapy Market (4th Edition), 2019-2030 (https://www.rootsanalysis.com/
• Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 (https://www.rootsanalysis.com/
+1 (415) 800 3415
+44 (122) 391 1091